News
1d
TipRanks on MSNIdeaya Biosciences, Hengrui announce oral presentation at IASLC 2025Ideaya Biosciences (IDYA) and Jiangsu Hengrui Pharmaceuticals Co. announced the publication of an abstract for an oral presentation on IDE849 at ...
The late-stage readout suggests that HRS9531 can hold its own against Eli Lilly’s blockbuster GLP-1/GIP agonist Zepbound, ...
7d
Clinical Trials Arena on MSNHengrui and Kailera report positive data from Phase III obesity treatment trialHengrui Pharma and Kailera Therapeutics have reported positive topline data from the former’s Phase III trial (HRS9531-301) ...
The molecule, developed in collaboration with Massachusetts-based Kailera Therapeutics, is headed for a new drug application ...
Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...
The results position Hengrui to seek approval of the Zepbound-like drug in China, and Kailera, a well-funded startup, to ...
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...
Hengrui Pharma delivered a strong international presence, featuring 15 innovative drugs and 72 research outcomes. These included 4 oral presentations, 5 rapid oral presentations, 27 poster ...
A Hengrui drug that interferes with a cancer cell’s DNA damage response is heading to Merck KGaA for €160 million up front and up to €1.4 billion tied to milestones.
Hengrui also has drugs in Phase I clinical trials in the U.S. “I wouldn’t say that our lab is more productive than a lab operated by a multinational drug firm,” Tao says.
Jiangsu Hengrui Pharmaceuticals Co. has started taking investor orders for a Hong Kong listing that could raise as much as HK$9.9 billion ($1.3 billion), the latest significant deal to boost the ...
Jiangsu Hengrui Pharmaceuticals Co. is considering a second listing in Hong Kong that could happen as soon as next year, according to people familiar with the situation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results